Last reviewed · How we verify
IMA203CD8 Product
At a glance
| Generic name | IMA203CD8 Product |
|---|---|
| Sponsor | Immatics US, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMA203CD8 Product CI brief — competitive landscape report
- IMA203CD8 Product updates RSS · CI watch RSS
- Immatics US, Inc. portfolio CI